Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma

Table 4

Association of serum MMP9 with time to progression (TTP) and overall survival (OS).

Serum MMP9	TTP				OS
	HR (95% CI)		HR (95% CI) adj^a	adj^a	HR (95% CI)		HR (95% CI) adj^b	adj^b
Before treatment (ng/ml)	1.020 (0.981-1.061)^c	0.309	1.020 (0.981-1.061)^c	0.464	1.033 (0.985-1.084)^c	0.180	1.027 (0.977-1.080)^c	0.293
After chemotherapy (ng/ml)	1.025 (0.965-1.089)^c	0.420	1.011 (0.948-1.077)^c	0.748	1.027 (0.951-1.109)^c	0.494	1.007 (0.929-1.092)^c	0.868
Change after chemotherapy (ng/ml)	0.985 (0.942-1.029)^c	0.488	0.981 (0.936-1.028)^c	0.417	0.973 (0.923-1.025)^c	0.300	0.966 (0.916-1.020)^c	0.209
Change after chemotherapy—increase vs. decrease	0.689 (0.393-1.207)	0.193	0.681 (0.384-1.208)	0.189	0. 256 (0.306-1.276)	0.197	0.586 (0.286-1.198)	0.143
At disease progression (ng/ml)					0.997 (0.929-1.069)^c	0.929	0.975 (0.900-1.056)^c	0.532

^aAdjusted for C-reactive protein and histological type. ^bAdjusted for C-reactive protein. ^cHazard ratios (HRs) calculated for increase of MMP9 levels for 100 ng/ml.